Results 21 to 30 of about 3,556,677 (271)
Dexmedetomidine Reduced Cytokine Release during Postpartum Bleeding-Induced Multiple Organ Dysfunction Syndrome in Rats [PDF]
Dexmedetomidine (DEX) is an α2-adrenergic agonist. It decreases the levels of norepinephrine release, resulting in a reduction of postsynaptic adrenergic activity.
Liu Xianbao +4 more
doaj +2 more sources
Efficacy of sarilumab and dexamethasone co-administration for lowering multiple blood biomarkers in the treatment of cytokine release syndrome in hospitalized covid-19 patients [PDF]
The current study was planned to explore the potential synergistic role of the co-administration of sarilumab and dexamethasone in reducing blood biomarkers associated with cytokine release syndrome in hospitalised patients of coronavirus disease-2019 ...
Ishtiaq Ahmad, Hamidullah
doaj +2 more sources
We discovered a novel therapeutic target critical for SARS-CoV-2, cellular infectivity and the induction of the cytokine release syndrome. Here, we show that the mammalian enzyme neuraminidase-1 (Neu-1) is part of a highly conserved signaling platform ...
William W. Harless +4 more
doaj +2 more sources
Background: Cytokine Release Syndrome (CRS) is a hyperinflammatory state triggered by immune therapies like CAR T-cell therapy and bispecific T-cell engagers (BiTEs).
Panos Arvanitis +3 more
doaj +2 more sources
Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy
Shira Cohen, Pnina FishmanCan-Fite BioPharma Ltd., Kiryat-Matalon, Petah-Tikva 49170, IsraelAbstract: Cancer patients undergoing immunotherapy may develop cytokine release syndrome (CRS), an inflammatory cytokine storm condition, followed by neurotoxic ...
Cohen S, Fishman P
doaj +1 more source
Cytokine Release Syndrome: A Case Report. [PDF]
Although generally well tolerated, immune checkpoint inhibitors can occasionally lead to severe immune-related adverse events, including cytokine release syndrome (CRS), a condition resulting from excessive immune activation and cytokine secretion, specifically interleukin-6 (IL-6).
Silva IF +4 more
europepmc +3 more sources
Supplementary Data from Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell–Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR ...
Chakkapong Burudpakdee (11247636) +25 more
core +3 more sources
Cytokine release syndrome in solid tumors. [PDF]
Abstract Cytokine release syndrome (CRS) is a common and potentially severe complication of cancer immunotherapy, including CAR T‐cell therapies, bispecific T‐cell engagers, and less commonly immune checkpoint inhibitors. Although extensive research has established guidelines for managing CRS in hematological malignancies, there is a ...
Synnott D +3 more
europepmc +4 more sources
Cytokine Release Syndrome Following Blinatumomab Therapy [PDF]
New therapeutic solutions have emerged in the last few decades with the growth and expansion of the field of cancer research. Amongst these new agents, immunotherapy has been prominent, particularly regarding the treatment of hematologic malignancies.
Ojemolon, Pius E +4 more
openaire +2 more sources
Introduction Patients with coronavirus disease, especially solid organ transplant recipients, are more susceptible to developing cytokine release syndrome than those with other viral infections.
Daiji Takamoto +9 more
doaj +1 more source

